Cancer is the most common disease-related cause of death in Australian children. Although survival rates have improved significantly, the outlook remains dismal for children with aggressive subtypes of neuroblastoma and sarcoma. Ruby specialises in the use of mass spectrometry – a technology she believes has great potential to increase understanding of highly aggressive neuroblastomas. Using this platform to analyse tumour and blood samples, she aims to find underlying metabolic changes that can indicate aggressiveness. Taking a blood sample is a far less invasive procedure than a tumour biopsy, causing less anxiety for the child in the clinical setting. Ruby hopes her research will result in more effective diagnosis and treatment for children battling these devastating diseases.